drugset
drugset / Trial / NCT06786780

Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids

NCT06786780 ↗

Phase 2 Enrolling by invitation 50 enrolled Chongqing University Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, single-center, open-label, Phase II study aimed at assessing the efficacy of organoids in predicting the response to radiotherapy and chemotherapy in cervical cancer

Timeline

Start
2023-01-01
Primary completion
2025-06-01
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 40 mg/m2 —
Subject Cisplatin Other / unclassified 100 mg/m2 —

Indications

cervical cancer